| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC16A4 |
| Uniprot No | O15374 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 196–299aa |
| 氨基酸序列 | RPIHIKSENNSGIKDKGSSLSAHGPEAHATETHCHETEESTIKDSTTQKAGLPSKNLTVSQNQSEEFYNGPNRNRLLLKSDEESDKVISWSCKQLFDISLFRNP |
| 预测分子量 | 17.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC16A4重组蛋白的参考文献示例(内容为虚构，仅供格式参考)：
1. **标题**: "Recombinant expression and functional characterization of human SLC16A4 as a monocarboxylate transporter"
**作者**: Smith J, et al.
**摘要**: 研究通过HEK293细胞重组表达了人源SLC16A4蛋白，证实其介导乳酸和酮体的跨膜转运，并发现其活性受pH调控，为代谢研究提供工具。
2. **标题**: "Structural insights into SLC16A4 through cryo-EM analysis of the recombinant protein"
**作者**: Zhang Y, et al.
**摘要**: 利用重组SLC16A4蛋白进行冷冻电镜结构解析，揭示了底物结合域的关键氨基酸残基，阐明了其选择性转运机制。
3. **标题**: "SLC16A4 recombinant protein modulates immune responses in a murine autoimmune model"
**作者**: Lee H, et al.
**摘要**: 通过原核系统表达并纯化SLC16A4重组蛋白，在小鼠模型中证明其通过调节T细胞代谢抑制自身免疫反应，提示治疗潜力。
4. **标题**: "Development of a high-throughput assay for SLC16A4 inhibitors using recombinant protein"
**作者**: Brown K, et al.
**摘要**: 基于重组SLC16A4的荧光底物转运实验，建立了药物筛选平台，筛选出小分子抑制剂，为癌症靶向治疗提供先导化合物。
(注：以上文献为示例性内容，实际文献需通过学术数据库检索确认。)
**Background of SLC16A4 Recombinant Protein**
The SLC16A4 gene encodes a member of the solute carrier family 16 (SLC16), a group of monocarboxylate transporters (MCTs) responsible for shuttling metabolites like lactate, pyruvate, and ketone bodies across cell membranes. SLC16A4. also termed MCT5. is a less-characterized isoform compared to its well-studied homologs (e.g., MCT1-4). It is predicted to function as a proton-coupled transporter, supporting metabolic homeostasis and intercellular communication in tissues such as the kidney, liver, and immune system. Dysregulation of MCTs is linked to metabolic disorders, cancer progression, and immune dysfunction, highlighting their therapeutic relevance.
Recombinant SLC16A4 protein is engineered for in vitro studies to elucidate its structural and functional properties. Produced via heterologous expression systems (e.g., mammalian cells or bacteria), it retains transmembrane domains and substrate-binding regions critical for transport activity. Purification often involves affinity tags (e.g., His-tag) for isolation and characterization. Researchers utilize this tool to investigate substrate specificity, regulation by pH or hormones, and interactions with ancillary proteins like CD147/Basigin, which stabilize MCTs in membranes.
Current studies focus on SLC16A4's role in metabolic reprogramming in cancers, immune cell metabolism, and renal handling of metabolites. Its recombinant form also aids in drug discovery, enabling high-throughput screening for inhibitors or modulators targeting MCT-related pathologies. Despite limited functional data, SLC16A4’s conservation across species and tissue-specific expression suggest unique physiological roles, warranting further exploration to define its contributions to health and disease.
×
